AMTI
Applied Molecular Transport Inc.
Set alert
52-week range unavailable
- Open
- 0.313
- Prev close
- 0.263
- Mkt cap
- 11.01M
- Vol
- 235.21K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.263
- High
- 0.313
- Forward P/E
- -0.35
- Beta
- 2.29
- Short ratio
- 0.75
- Inst. own
- 37.28%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2023
- 50-d avg
- 0.193824
- 200-d avg
- 0.246063
- 1y target
- 1.00
Key statistics
- Market cap
- 11.01M
- Enterprise value
- -5.88M
- Trailing P/E
- 0.00
- Forward P/E
- -0.35
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.66
- EPS (TTM)
- -1.89
- Beta
- 2.29
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -27.23M
- Total cash
- 18.10M
- Total debt
- 1.35M
- Return on equity
- -158.05%
- Shares outstanding
- 41.85M
- Short % of float
- 0.81%
- 50-day average
- 0.193824
- 200-day average
- 0.246063
Analyst view
Consensus: hold
Next earnings
Nov 9, 2023
Expected Nov 9, 2023. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2023 | Sep 1, 2023 | -0.50 | — | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.77 | — | — | — |
| May 11, 2023 | Mar 1, 2023 | -0.61 | — | — | — |
| Mar 9, 2023 | Dec 1, 2022 | -0.66 | — | — | — |
| Nov 7, 2022 | Sep 1, 2022 | -0.66 | — | — | — |
| Aug 4, 2022 | Jun 1, 2022 | -0.65 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 27, 2023 | Chardan Capital | down | Buy | Neutral |
| Mar 5, 2023 | Chardan Capital | reit | — | Buy |
| Feb 7, 2023 | Jefferies | down | Hold | Underperform |
| Jan 4, 2023 | B of A Securities | down | Buy | Underperform |
| Dec 26, 2022 | SVB Leerink | down | Outperform | Market Perform |
| Dec 22, 2022 | JMP Securities | down | Market Outperform | Market Perform |
About Applied Molecular Transport Inc.
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trials to treat patients with chronic pouchitis, as well as is in Phase II development to treat patients with rheumatoid arthritis. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral and respiratory biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California. As of December 27, 2023, Applied Molecular Transport Inc. operates as a subsidiary of Cyclo Therapeutics, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- appliedmt.com
News
- Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
- APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - AMTI
- Applied Molecular Transport Reports Third Quarter 2023 Financial Results
- APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - AMTI
- Why Flux Power Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
- Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement
- Why NextGen Healthcare Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
- Applied Molecular Transport Reports Second Quarter 2023 Financial Results
- Stocks That Hit 52-Week Lows On Tuesday
- Stocks That Hit 52-Week Lows On Monday
Your note
Sign in to keep a note on AMTI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BHATT ELIZABETH | Officer | Stock Award(Grant) | Feb 14, 2022 | 48,750 |
| CROSS SHAWN M. | Chief Executive Officer | Sale | Nov 21, 2023 | 545,499 |
| EPIQ CAPITAL GROUP, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 12, 2022 | 0 |
| HANTS BRANDON | Chief Financial Officer | Sale | Nov 21, 2023 | 301,225 |
| KANWAR BITTOO | Officer | Sale | Feb 28, 2023 | 78,005 |
| LAMOND DAVID A. | Director | Purchase | May 22, 2022 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| EPIQ Capital Group, LLC | 22.05% | 8,694,264 | 2.24M | Jun 29, 2023 |
| Founders Fund V Management, LLC | 9.16% | 3,611,615 | 931.80K | Jun 29, 2023 |
| Vanguard Group Inc | 3.42% | 1,349,867 | 348.26K | Jun 29, 2023 |
| Founders Fund VI Management, LLC | 2.10% | 826,607 | 213.26K | Jun 29, 2023 |
| Blackrock Inc. | 1.28% | 504,835 | 130.25K | Jun 29, 2023 |
| Laurion Capital Management, LP | 0.98% | 387,383 | 99.94K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.76% | 1,089,900 | 281.19K | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 0.56% | 222,651 | 57.44K | Jun 29, 2023 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.25% | 100,000 | 25.80K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.22% | 87,519 | 23.30K | May 30, 2023 |
| BlackRock Advantage Small Cap Core Fund | 0.17% | 65,272 | 17.38K | May 30, 2023 |
| Fidelity Total Market Index Fund | 0.07% | 28,241 | 7.52K | May 30, 2023 |